Live Breaking News & Updates on Preventing Clinically Meaningful Progression

Stay updated with breaking news from Preventing clinically meaningful progression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy after 24 Weeks of Treatment Oral. | January 25, 2023 ....

Bret Shapiro , Corey Davis , Ocuphire Pharma , Mina Sooch , Peterk Kaiser , Early Treatment Diabetic Retinopathy Study Research Group , Macula Society Annual Meeting , Cole Eye Institute , Cleveland Clinic Foundation , Globenewswire Inc , Ocuphire Pharma Inc , Statistical Significance , Key Pre Specified Secondary Endpoint , Preventing Clinically Meaningful Progression , Diabetic Retinopathy , Favorable Safety , Tolerability Allowing , Potential Attractive Non Invasive Option , Both Eyes , Webcast Today , Eye Institute , Clinic Foundation , Clinical Importance , Diabetic Retinopathy Severity , Treatment Diabetic Retinopathy Study Research , Webcast Details ,